HypomagnesaemiaDisease1 paperHuman trial1LatestThe Lancet Oncology·5 JunCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialRandomised trial in 658 peopleKidneyPaper
The Lancet Oncology·5 JunCabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialRandomised trial in 658 peopleKidneyPaper